EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review

Jing Zhou, Nenghan Zhang, Jiajun Li, Xiangqi Qin, Lingqi Kong, Liang Bai, Tuo Han

Exploration of Endocrine and Metabolic Diseases · 13.08.2026 · 3

DOI: 10.37349/eemd.2026.101481 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Endocrine and Metabolic Diseases, online erschienen am 13.08.2026. Verfasst von Jing Zhou und 6 weiteren Autor:innen. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the rising global prevalence of obesity and type 2 diabetes, metabolic disorders have become major drivers of cardiovascular morbidity and mortality worldwide. Cardiovascular-kidney-metabolic (CKM) syndrome encompasses obesity, type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and cardiovascular disease (CVD), all of which share common pathophysiological pathways. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), a novel class of antihyperglycemic agents, have demonstrated pleiotropic effects—including weight reduction, blood pressure lowering, albuminuria reduction, decreased major adverse cardiovascular events (MACE), and slowed progression of renal dysfunction. These benefits position GLP-1RAs as a potential cornerstone therapy for CKM syndrome. This review synthesizes recent advances in GLP-1RA research within the CKM framework, explores their underlying mechanisms, and offers insights to refine diagnostic and therapeutic strategies for cardiometabolic diseases.

Zitieren

APA

Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026). Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review. Exploration of Endocrine and Metabolic Diseases, 3. https://doi.org/10.37349/eemd.2026.101481

Vancouver

Zhou J, Zhang N, Li J, Qin X, Kong L, Bai L, et al. Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review. Exploration of Endocrine and Metabolic Diseases. 2026;3. doi:10.37349/eemd.2026.101481

BibTeX
@article{Zhou2026,
  author = {Zhou, Jing and Zhang, Nenghan and Li, Jiajun and Qin, Xiangqi and Kong, Lingqi and Bai, Liang and Han, Tuo},
  title = {Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review},
  journal = {Exploration of Endocrine and Metabolic Diseases},
  year = {2026},
  volume = {3},
  doi = {10.37349/eemd.2026.101481}
}
Kostenlos starten →